Abstract
Implications of 3-Year Follow-up Data From the Childhood and Adolescent Migraine Prevention Medication Trial
Highlights
The current study[1] presents interval follow-up data over a 3-year period for participants who were initially enrolled in the drug phase of Childhood and Adolescent Migraine Prevention Medication (CHAMP) and primarily interrogates whether participants maintained therapeutic gains after completion of the drug phase
The initial CHAMP trial[2] provided compelling evidence of what we already suspected— that is, treating pediatric migraine is not treating adult migraine with lower doses—it simultaneously incited serious debate among practitioners treating and researching pediatric headache
It seems that left without intervention, whether pharmacological or behavioral, a subset of pediatric patients will experience an increase in headache burden throughout childhood and into adulthood
Summary
The current study[1] presents interval follow-up data over a 3-year period for participants who were initially enrolled in the drug phase of CHAMP and primarily interrogates whether participants maintained therapeutic gains after completion of the drug phase. Migraine prevalence steadily increased throughout adolescence (15% in female and 7% in male individuals) and adulthood (22% in female and 8% in male individuals).[4] it seems that left without intervention, whether pharmacological or behavioral, a subset of pediatric patients will experience an increase in headache burden throughout childhood and into adulthood.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
